Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from David Ricks

This Blue-Chip Stock Is Cooking Up a Major Growth Catalyst

Eli Lilly is poised for a major boost as new data shows its diabetes drug Mounjaro offers heart health benefits, potentially making it the top choice for patients with Type 2 diabetes.

Barchart

Dow Jones, S&P 500 Pharma Names Recover After Trump Backs Off His Tariffs Plan

Pharma names whipsawed Wednesday after Trump said he would enact "major" tariffs on drug imports and then backed off his tariffs — for now.

Investors Business Daily

Eli Lilly Stock Rises After Profit, Outlook Top Expectations

Eli Lilly stock is higher Thursday after the pharma giant beat fourth-quarter profit expectations and issued strong 2025 guidance. Here's what you need to know.

Kiplinger

From analysis to the latest developments in health,
read the most diverse news in one place.

Eli Lilly’s CEO pinpoints the 3-pronged problem big execs face with remote work

Managing a distributed workforce is “the leadership challenge of our decade,” David Ricks, CEO of pharma giant Eli Lilly, said.

Fortune

‘Hero’ journalist congratulated after Eli Lilly lowers price of insulin after his spoof tweet raised awareness

Eli Lilly’s CEO challenged other pharmaceutical companies to drop insulin prices as well

The Independent UK

US drug maker to slash some insulin prices, expand cost cap

President Joe Biden hails move by Eli Lilly as a ‘big deal’, calling on other manufacturers to also reduce prices.

Al Jazeera

Eli Lilly plans to slash prices of some older insulins, expand cost cap

Lawmakers and patient advocates have been pressuring drugmakers to take action on soaring drug prices.

Chicago Sun-Times

Read news from The Economist, FT, and more,
with one subscription

Diabetes Giant Eli Lilly Slashes Insulin Prices 70% In A Move Its CEO Calls 'Aggressive'

Eli Lilly announced a 70% price cut for most of its insulins Wednesday in a move its CEO described as "aggressive." Eli Lilly stock jumped.

Investors Business Daily

‘More work to do’: Eli Lilly admits insulin pricing could be lower amid Twitter chaos

Furor over platform’s verified profiles may have done some good, but challenges still plague the site after a mass worker exodus

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.